RPS6P17: A Promising Drug Target / Biomarker (G120318)

Target Name: RPS6P17

NCBI ID: G120318

RPS6P17

Other Name(s): ribosomal protein S6 pseudogene 17 | Ribosomal protein S6 pseudogene 17 | RPS6_7_1168

RPS6P17: A Promising Drug Target / Biomarker

The protein RPS6P17 is a key regulator of microtubules, which are essential for the proper functioning of eukaryotic cells. Microtubules play a crucial role in cell division, intracellular transport, and the regulation of various cellular processes. The loss of microtubules can lead to various cellular abnormalities, including the development of cancer. Therefore, the study of microtubule-associated proteins (MAPs) is important for understanding the mechanisms of cancer progression and drug development.

RPS6P17: A Drug Target and Potential Biomarker

The RPS6P17 gene encodes a protein that is highly conserved across various species, including humans. The protein has a molecular weight of approximately 180 kDa and a pre-alpha-helical region of 11.5% of its amino acid sequence. RPS6P17 is a member of the family of proteins known as kinesins, which are involved in the regulation of microtubule dynamics.

The RPS6P17 protein is involved in the assembly and disassembly of microtubules. It plays a crucial role in regulating the formation and stability of microtubules, as well as their dynamics. The RPS6P17 protein has been shown to interact with several microtubule-associated proteins, including TP103 and TP116. These interactions may play a role in the regulation of microtubule dynamics and the proper functioning of microtubules.

The RPS6P17 gene has also been implicated in various diseases, including cancer. Several studies have shown that the RPS6P17 gene is frequently deleted or mutated in various cancer types, including breast, ovarian, and colorectal cancers. These genetic alterations may contribute to the development of cancer and the maintenance of its progression. Therefore, the study of RPS6P17 as a potential drug target or biomarker is of great interest.

Drug Discovery and Therapeutic Use

The drug discovery process for RPS6P17 is an active area of research, with several studies showing promise in its potential as a drug target. One of the main strategies for drug discovery is the use of small molecules, such as inhibitors or modulators, to interact with the RPS6P17 protein and modulate its activity.

Several studies have shown that inhibitors of the RPS6P17 protein have the potential to slow down or inhibit microtubule dynamics. These inhibitors have been shown to disrupt the formation and stability of microtubules, which may contribute to the inhibition of cell division and the development of cancer. One of the most promising inhibitors is a small molecule called 1-fluorophosphonic acid (FPPA), which has been shown to inhibit the RPS6P17 protein and slow down microtubule dynamics in various cancer cell lines.

Another approach for drug discovery is the use of RNA-based therapeutics. In this approach, small interfering RNA (siRNA) molecules are designed to specifically target the RPS6P17 gene and inhibit its expression. SiRNA-based therapeutics have shown promise in the treatment of various diseases, including cancer. In the context of RPS6P17, siRNA-based therapeutics may be a promising approach for the treatment of cancer.

In addition to small molecules and siRNA-based therapeutics, another approach for drug discovery is the use of computational tools, such as molecular docking and molecular dynamics simulations. These tools can be used to identify potential binding partners and interactions of the RPS6P17 protein with small molecules or other proteins. In this context, computational tools may be useful in the identification of potential inhibitors or modulators of the RPS6P17 protein.

Conclusion

In conclusion, the RPS6P17 protein is a key regulator of microtubules and has been implicated in various diseases, including cancer. The study of RPS6P17 as a potential drug target or biomarker is an active area of research, with several studies showing promise in its potential as a therapeutic agent. The use of small molecules, siRNA-based therapeutics, and computational tools may be

Protein Name: Ribosomal Protein S6 Pseudogene 17

The "RPS6P17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS6P17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets